High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database
- 3 February 2012
- journal article
- research article
- Published by Taylor & Francis Ltd in Leukemia & Lymphoma
- Vol. 53 (6), 1113-1116
- https://doi.org/10.3109/10428194.2011.639882
Abstract
We aimed to characterize surveillance imaging and circumstances of relapse for patients with diffuse large B-cell lymphoma (DLBCL) in the National Comprehensive Cancer Network Non-Hodgkin's Lymphoma Outcomes Database, a prospective cohort study collecting clinical and outcome data at seven comprehensive cancer centers. Patients presenting with newly diagnosed DLBCL in remission ≥3 months after initial therapy and who had accrued 2 years of follow-up were eligible for analysis (n = 625). The median number of imaging studies was 2.5/year (institutional range 0.5–3.5, p < 0.0001); 48.4% received only dedicated computed tomography (CT) scans, 14.6% received only positron emission tomography (PET)-inclusive modalities, 32.8% received a combination and 4.2% received no imaging. Among all eligible patients, 50 (8.0%) experienced relapse, and approximately one-quarter of subclinical relapses were detected through routine imaging. Our results suggest that despite limited data regarding its effect on outcomes, surveillance imaging is prevalent in DLBCL, and a majority of patients receive PET scans at some point during follow-up.Keywords
This publication has 16 references indexed in Scilit:
- Radiation Dose Associated With Common Computed Tomography Examinations and the Associated Lifetime Attributable Risk of CancerArchives of Internal Medicine, 2009
- Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of LymphomaJournal of Clinical Oncology, 2009
- Comparison of Referring and Final Pathology for Patients With Non-Hodgkin's Lymphoma in the National Comprehensive Cancer NetworkJournal of Clinical Oncology, 2008
- 18F-FDG PET as a Routine Test for Posttherapy Assessment of Hodgkin's Disease and Aggressive Non-Hodgkin's Lymphoma: Where Is the Evidence?: TABLE 1Journal of Nuclear Medicine, 2007
- The role of FDG-PET scans in patients with lymphomaBlood, 2007
- Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient populationAnnals Of Oncology, 2006
- Response Assessment of Aggressive Non-Hodgkin’s Lymphoma by Integrated International Workshop Criteria and Fluorine-18–Fluorodeoxyglucose Positron Emission TomographyJournal of Clinical Oncology, 2005
- The Role of Surveillance CT Scans in Patients with Diffuse Large B-cell Non-Hodgkin's LymphomaLeukemia & Lymphoma, 2003
- Detection of relapse in non‐Hodgkin's lymphoma: Role of routine follow‐up studiesAmerican Journal of Hematology, 2001
- The Utility of Follow-up Testing After Curative Cancer Therapy: A Critical Review and Economic AnalysisJournal of General Internal Medicine, 1997